metabolic syndrome.
Conditions
Interventions
Intervention 1: Intervention group: Receiving a single dose of curcumin (500 mg) for 12 weeks. Patients receive their supplement every four weeks. Supplement should be eaten with food. Intervention 2:
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 70 Years
Inclusion criteria
Inclusion criteria: Willingness to participate in the study and the completion of informed consent form Metabolic syndrome Patients
Exclusion criteria
Exclusion criteria: Curcumin sensitivity Regular use of anti-diabetes drugs, antiplatelet drugs, antioxidant supplements, anti-inflammatory drugs, analgesics Use of multivitamin or herbal supplements at least 3 months before the start of the study Liver disease, autoimmune disease, biliary disease, obstructive disease, diabetes, kidney failure, malignancy, kidney stones, calcium oxalate stones Pregnancy and breastfeeding Drug abuse Smoking hookah or cigarettes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pulse wave velocity. Timepoint: At the beginning and the end of the study. Method of measurement: Sphygmocor xcel.;Central Augmentation Index. Timepoint: At the beginning and the end of the study. Method of measurement: Sphygmocor xcel.;Central Augmentation Index75. Timepoint: At the beginning and the end of the study. Method of measurement: Sphygmocor xcel.;Central augmentation pressure. Timepoint: At the beginning and the end of the study. Method of measurement: Sphygmocor xcel.;Brachial blood pressure. Timepoint: At the beginning and the end of the study. Method of measurement: Sphygmocor xcel.;Central blood pressure. Timepoint: At the beginning and the end of the study. Method of measurement: Sphygmocor xcel. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAbdolreza Norouzy
Mashhad University of Medical Sciences
Outcome results
None listed